My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 331

    1.

    Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.

    Heise T, Nosek L, Rønn BB, Endahl L, Heinemann L, Kapitza C, Draeger E.

    Diabetes. 2004 Jun;53(6):1614-20.PMID: 15161770 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes.

    Danne T, Lüpke K, Walte K, Von Schuetz W, Gall MA.

    Diabetes Care. 2003 Nov;26(11):3087-92.PMID: 14578244 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.

    Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J.

    Clin Ther. 2004 May;26(5):724-36.PMID: 15220016 [PubMed - indexed for MEDLINE]Related articles

    4.

    Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus.

    Wutte A, Plank J, Bodenlenz M, Magnes C, Regittnig W, Sinner F, Rønn B, Zdravkovic M, Pieber TR.

    Exp Clin Endocrinol Diabetes. 2007 Jul;115(7):461-7.PMID: 17647145 [PubMed - indexed for MEDLINE]Related articles

    5.

    Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.

    Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T.

    Diabetes Obes Metab. 2007 May;9(3):290-9.PMID: 17391154 [PubMed - indexed for MEDLINE]Related articles

    6.

    A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.

    Plank J, Bodenlenz M, Sinner F, Magnes C, Görzer E, Regittnig W, Endahl LA, Draeger E, Zdravkovic M, Pieber TR.

    Diabetes Care. 2005 May;28(5):1107-12.PMID: 15855574 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.

    Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J.

    Diabet Med. 2007 Jan;24(1):27-34.PMID: 17227321 [PubMed - indexed for MEDLINE]Related articles

    8.

    Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.

    Fulcher GR, Gilbert RE, Yue DK.

    Intern Med J. 2005 Sep;35(9):536-42.PMID: 16105155 [PubMed - indexed for MEDLINE]Related articles

    9.

    Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes.

    Bott S, Tusek C, Jacobsen LV, Endahl L, Draeger E, Kapitza C, Heise T.

    Diabet Med. 2006 May;23(5):522-8.PMID: 16681561 [PubMed - indexed for MEDLINE]Related articles

    10.

    Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study.

    Porcellati F, Rossetti P, Busciantella NR, Marzotti S, Lucidi P, Luzio S, Owens DR, Bolli GB, Fanelli CG.

    Diabetes Care. 2007 Oct;30(10):2447-52. Epub 2007 Jul 10. Erratum in: Diabetes Care. 2008 Jan;31(1):188. PMID: 17623819 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.

    Vague P, Selam JL, Skeie S, De Leeuw I, Elte JW, Haahr H, Kristensen A, Draeger E.

    Diabetes Care. 2003 Mar;26(3):590-6.PMID: 12610006 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.

    Rossetti P, Pampanelli S, Fanelli C, Porcellati F, Costa E, Torlone E, Scionti L, Bolli GB.

    Diabetes Care. 2003 May;26(5):1490-6.PMID: 12716810 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.

    Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M.

    Diabetes Care. 2001 Feb;24(2):296-301.PMID: 11213882 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin.

    Porcellati F, Rossetti P, Pampanelli S, Fanelli CG, Torlone E, Scionti L, Perriello G, Bolli GB.

    Diabet Med. 2004 Nov;21(11):1213-20.PMID: 15498088 [PubMed - indexed for MEDLINE]Related articles

    15.

    Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.

    Rosenstock J, Park G, Zimmerman J; U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.

    Diabetes Care. 2000 Aug;23(8):1137-42.PMID: 10937511 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.

    Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W.

    Diabetes Obes Metab. 2005 Jan;7(1):56-64.PMID: 15642076 [PubMed - indexed for MEDLINE]Related articles

    17.

    Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes.

    Ashwell SG, Amiel SA, Bilous RW, Dashora U, Heller SR, Hepburn DA, Shutler SD, Stephens JW, Home PD.

    Diabet Med. 2006 Mar;23(3):285-92.PMID: 16492212 [PubMed - indexed for MEDLINE]Related articles

    18.

    Is insulin detemir able to favor a lower variability in the action of injected insulin in diabetic subjects?

    Valensi P, Cosson E.

    Diabetes Metab. 2005 Sep;31(4 Pt 2):4S34-4S39. Review.PMID: 16389896 [PubMed - indexed for MEDLINE]Related articles

    19.

    Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus.

    Roach P, Bai S, Charbonnel B, Consoli A, Taboga C, Tiengo A, Bolli G; High Mix Study Group.

    Clin Ther. 2004 Apr;26(4):502-10.PMID: 15189747 [PubMed - indexed for MEDLINE]Related articles

    20.

    Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial.

    Home P, Bartley P, Russell-Jones D, Hanaire-Broutin H, Heeg JE, Abrams P, Landin-Olsson M, Hylleberg B, Lang H, Draeger E; Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group.

    Diabetes Care. 2004 May;27(5):1081-7.PMID: 15111525 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity